Christopher Gulka

Q: What is Christopher Gulka email address?

Email Christopher Gulka at chrisgulka22@gmail.com. This email is the most updated Christopher Gulka email found in 2026.

Q: How to contact Christopher Gulka?

To contact Christopher Gulka send an email to chrisgulka22@gmail.com. If you want to call Christopher Gulka try calling on +16178035198 and +15085330761.

Principal Scientist at Sunbird Bio | Melrose, Massachusetts, United States

About Christopher Gulka

Christopher Gulka serves as Principal Scientist at Sunbird Bio, where he plays a pivotal role in advancing the Glympse liquid biopsy production platform following the strategic merger with Glympse Bio. In this capacity, Christopher is at the forefront of innovative research aimed at assessing protease activity in blood, a critical biomarker for the early detection and monitoring of oncological diseases. His expertise in chemistry and nanotechnology enables him to develop sophisticated assays that leverage dynamic light scattering and fluorescence techniques, facilitating the precise measurement of protease activity.

Christopher's interdisciplinary training has equipped him with a unique skill set that allows him to effectively troubleshoot and overcome challenges in assay development and data analysis. His proficiency in peptide synthesis and phase contrast imaging further enhances his ability to design and optimize experiments that yield reliable and reproducible results. By integrating advanced nanomaterials into the liquid biopsy platform, he is contributing to the development of cutting-edge diagnostic tools that promise to revolutionize cancer detection and treatment.

As a leader in this space, Christopher is not only focused on the technical aspects of his work but also on fostering collaboration across teams to drive innovation. His commitment to translating complex scientific concepts into practical applications positions him as a key player in the ongoing evolution of liquid biopsy technologies. Through his efforts, Christopher is helping to pave the way for more effective and less invasive cancer diagnostics, ultimately improving patient outcomes in the field of oncology.

Christopher Gulka Work